

REGENERON PHARMACEUTICALS INC

Form 8-K

April 03, 2007

Table of Contents

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities and Exchange Act of 1934

Date of Report (Date of earliest event reported): April 3, 2007 (March 30, 2007)

REGENERON PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)

New York

000-19034

133444607

(State or other jurisdiction
of incorporation)

(Commission File Number)

**(I.R.S. Employer
Identification Number)**

**777 Old Saw Mill River Road, Tarrytown, New
York**

10591-6707

(Address of principal executive offices)

(Zip Code)

(914) 347-7000

(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

TABLE OF CONTENTS

Item 1.01 Entry into a Material Definitive Agreement

Item 9.01 Financial Statements and Exhibits

Exhibit Index

EX-99.A: PRESS RELEASE

Table of Contents

Item 1.01 Entry into a Material Definitive Agreement

On March 30, 2007, Regeneron announced that it had entered into a non-exclusive license agreement with Astellas Pharma Inc. (Astellas) granting Astellas certain rights to use Regeneron's VelocImmune[®] technology to discover human monoclonal antibodies. Pursuant to the terms of the agreement, Astellas will make a \$20 million upfront payment to Regeneron and Astellas will make up to five additional annual payments of \$20 million, subject to its ability to terminate the agreement after making the first three additional payments or if the technology does not meet minimum performance criteria. Regeneron is entitled to receive a mid-single-digit royalty on any future sales of antibody products discovered by Astellas using Regeneron's VelocImmune technology.

A copy of the press release announcing the agreement is furnished as Exhibit 99(a) to this Form 8-K.

Item 9.01 Financial Statements and Exhibits

(c) Exhibits

99(a) Press Release of Regeneron Pharmaceuticals, Inc. dated March 30, 2007.

Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

REGENERON PHARMACEUTICALS, INC.

Dated: April 3, 2007

By: /s/ Stuart Kolinski
Stuart Kolinski
Vice President and General Counsel

2

Table of Contents

Exhibit Index

| Number | Description |
|---------------|--|
| 99(a) | Press Release of Regeneron Pharmaceuticals, Inc. dated March 30, 2007. |

3